- Home
- NISN vs CMMB Comparison
NISN vs CMMB Comparison
Compare NISN & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NISN
- CMMB
- Stock Information
- Founded
- NISN 2005
- CMMB 2004
- Country
- NISN China
- CMMB Israel
- Employees
- NISN N/A
- CMMB N/A
- Industry
- NISN Metal Fabrications
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- NISN Industrials
- CMMB Health Care
- Exchange
- NISN Nasdaq
- CMMB Nasdaq
- Market Cap
- NISN 19.6M
- CMMB 22.0M
- IPO Year
- NISN 2016
- CMMB N/A
- Fundamental
- Price
- NISN $3.91
- CMMB $0.95
- Analyst Decision
- NISN
- CMMB Strong Buy
- Analyst Count
- NISN 0
- CMMB 2
- Target Price
- NISN N/A
- CMMB $8.50
- AVG Volume (30 Days)
- NISN 32.5K
- CMMB 125.0K
- Earning Date
- NISN 04-29-2025
- CMMB 08-20-2025
- Dividend Yield
- NISN N/A
- CMMB N/A
- EPS Growth
- NISN N/A
- CMMB N/A
- EPS
- NISN 1.43
- CMMB N/A
- Revenue
- NISN $340,219,546.00
- CMMB N/A
- Revenue This Year
- NISN N/A
- CMMB N/A
- Revenue Next Year
- NISN N/A
- CMMB N/A
- P/E Ratio
- NISN $17.73
- CMMB N/A
- Revenue Growth
- NISN 8.05
- CMMB N/A
- 52 Week Low
- NISN $3.22
- CMMB $0.87
- 52 Week High
- NISN $22.55
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- NISN 44.89
- CMMB 17.79
- Support Level
- NISN $3.85
- CMMB $0.87
- Resistance Level
- NISN $4.32
- CMMB $1.01
- Average True Range (ATR)
- NISN 0.32
- CMMB 0.06
- MACD
- NISN -0.02
- CMMB -0.01
- Stochastic Oscillator
- NISN 5.71
- CMMB 23.78
About NISN NiSun International Enterprise Development Group Co. Ltd.
NiSun International Enterprise Development Group Co Ltd is a provider of supply chain solutions and integrated financial services. Nisun is dedicated to providing professional supply chain solutions to Chinese and foreign enterprises and financial institutions. Through its subsidiaries, it is engaged in delivering supply chain solutions, and supply chain trading services to its customers across different industries. The company also provides financial solutions to small and mid-sized enterprises within the supply chain ecosystem. Using its fintech platforms, it provides various financing options, including supply chain financing, trade financing, and receivables financing. Geographically, its operations are predominantly focused on markets within the People's Republic of China.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.